Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting-Reference-Cited by-同舟云学术

Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting

Published:2019-01-29 Issue:5 Volume:74 Page:1363-1367
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

d’Arminio Monforte Antonella¹,Cozzi-Lepri Alessandro²,Di Biagio Antonio³^ORCID,Marchetti Giulia¹,Lo Caputo Sergio⁴,Rusconi Stefano⁵,Gianotti Nicola⁶,Mazzotta Valentina⁷,Mazzarello Giovanni³,Costantini Andrea⁸,Castagna Antonella⁶,Antinori Andrea⁷,

Affiliation:

1. Clinic of Infectious and Tropical Diseases, Department of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy

2. Institute for Global Health, University College London, London, UK

3. Infectious Diseases Unit, Hospital Policlinico San Martino, University of Genoa, Genoa, Italy

4. Clinic of Infectious Diseases, Policlinico, University of Bari, Bari, Italy

5. Infectious Diseases Unit, ASST FBF-Sacco, DIBIC ‘L. Sacco’, University of Milan, Milan, Italy

6. Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy

7. HIV/AIDS Department, INMI ‘L. Spallanzani’ IRCCS, Rome, Italy

8. Clinical Immunology Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Marche Polytechnic University, Ancona, Italy

Funder

ICONA Foundation

Gilead Sciences, Janssen, Merck Sharp and Dohme

ViiV Healthcare

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/74/5/1363/28501083/dky566.pdf

Reference15 articles.

1. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial;Lennox;Lancet,2009

2. Co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir versus co-formulated efavirenz, emtricitabine and tenofovir for initial treatment of HIV-1 infection: a randomised, double blind, phase 3 trial, analysis of results after 48 weeks;Sax;Lancet,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort;International Journal of Antimicrobial Agents;2024-01

2. Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice;Drug Design, Development and Therapy;2023-12

3. Management of Integrase Inhibitor-Associated Weight Gain: A Practical Clinical Approach;Current Infectious Disease Reports;2023-05-08

4. The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI;Frontiers in Public Health;2023-04-27

5. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review;Expert Review of Anti-infective Therapy;2023-04-20